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Comparison of tCGA and GeNIe 
genomic datasets for the detection 
of clinically actionable alterations 
in breast cancer
pushpinder Kaur1,2, Tania B. porras1,2, Alexander Ring1,2, John D. Carpten2,3 & Julie E. Lang1,2
Whole exome sequencing (WES), targeted gene panel sequencing and single nucleotide polymorphism 
(SNP) arrays are increasingly used for the identification of actionable alterations that are critical to 
cancer care. Here, we compared The Cancer Genome Atlas (TCGA) and the Genomics Evidence Neoplasia 
Information Exchange (GENIE) breast cancer genomic datasets (array and next generation sequencing 
(NGS) data) in detecting genomic alterations in clinically relevant genes. We performed an in silico 
analysis to determine the concordance in the frequencies of actionable mutations and copy number 
alterations/aberrations (CNAs) in the two most common breast cancer histologies, invasive lobular and 
invasive ductal carcinoma. We found that targeted sequencing identified a larger number of mutational 
hotspots and clinically significant amplifications that would have been missed by WES and SNP arrays 
in many actionable genes such as PIK3CA, EGFR, AKT3, FGFR1, ERBB2, ERBB3 and ESR1. The striking 
differences between the number of mutational hotspots and CNAs generated from these platforms 
highlight a number of factors that should be considered in the interpretation of array and NGs-based 
genomic data for precision medicine. Targeted panel sequencing was preferable to WES to define the 
full spectrum of somatic mutations present in a tumor.
A comprehensive understanding of potentially actionable genomic aberrations in tumor samples is important 
in guiding precision medicine for clinical decision-making. With the development of next-generation sequenc-
ing (NGS) technologies, it is feasible to characterize the individual genomic landscape and to identify disease 
causal variation for diagnosis and therapy. The recent advances in cancer genomics using targeted enrichment 
sequencing have reliably identified clinically relevant genomic alterations present in solid tumors1. However, the 
functional significance of these alterations is still unexplored and for most patients with metastatic breast cancer, 
there is a compelling need for selecting clinically relevant beneficial treatment strategies via the identification of 
genetic alterations driving tumorigenesis.
Large-scale efforts such as the Catalogue of Somatic Mutations (COSMIC), The Cancer Genome Atlas 
(TCGA) and American Association for Cancer Research (AACR) Genomics Evidence Neoplasia Information 
Exchange (GENIE) project were designed to help investigators better understand the impact of somatic mutations 
in cancer. However, the vast heterogeneity of lesions observed in mutations and copy number alterations (CNAs) 
varies for different genes and tumor histologies2–4. Molecular profiling of somatic mutations is increasingly being 
used to help select new treatment regimens in metastatic disease, although as yet there is no proven survival 
advantage for this approach. This is a particular concern since the open-label randomized, controlled SHIVA trial 
found that the use of molecularly targeted agents outside of their indications does not improve progression-free 
survival when compared to empirical treatment in heavily pre-treated metastatic patients5. Others have noted 
that genomics has not failed, it is just it its early stages of adoption and that N-of-One designs are necessary 
to adopt personalized medicine since each tumor has such unique biology6. The United States Food and Drug 
Administration (FDA) has recently approved the NGS-based FoundationOne CDx test that identifies actionable 
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alterations in cancer-related genes and can guide treatment decisions. Likewise, a variety of commercial and 
academic laboratories engage in NGS, with discussion of results at molecular tumor boards to discuss if findings 
indicate a druggable treatment target7–9. However, several technical issues need to be addressed before imple-
menting NGS results into clinical practice. These include consideration of the downstream molecular analysis 
of: degraded DNA extracted from formalin-fixed, paraffin-embedded (FFPE) specimens, limited amounts of 
fresh tissue, the degree of stromal cellularity, and variation in the sequencing depth and capture efficiency. These 
challenges limit the ability to identify clinically relevant aberrations present in cancer cell subpopulations7,10,11. 
In addition, another challenge arising in the analysis of multiple datasets is to identify consistent and reproduc-
ible clinically actionable biomarkers from sequencing technologies across cohorts and laboratory platforms. A 
comprehensive understanding of the detection of genomic alterations in cancer requires an integrative network 
framework for the analysis of NGS data.
The objective of our study was to investigate which platform (array versus WES and targeted panel sequenc-
ing) was most sensitive in identifying clinically significant genomic alterations using the TCGA and GENIE 
datasets for non-metastatic breast cancer patients.
Results
Comparison of the clinicopathological features of TCGA and GENIE cohorts. The clinical charac-
teristics including age, race, ethnicity, tumor grade and hormone receptor status were compared between TCGA 
and GENIE breast cancer invasive lobular carcinomas (ILC) and invasive ductal carcinomas (IDC) patients 
(Table 1). No significant differences were found for the mean age of patients for ILC (p = 0.66) and IDC (p = 0.66) 
patients in TCGA and GENIE datasets. Tumor grade and hormone receptor information were not available from 
the GENIE dataset.
Comparison of the number of mutational hotspots in actionable genes in breast cancer tCGA 
and GENIE datasets. Since WES, SNP arrays and targeted gene-panel approaches are routinely used to 
assess alterations in the coding regions of the genome, we sought to evaluate which of these technologies was 
more suitable for providing evidence of alterations in actionable targets. Overall, the results showed that there 
was inconsistency in the genomic alterations (including the percentages of mutational hotspots and CNAs) in the 
GENIE and TCGA datasets. We also compared the percentage of mutational hotspots between the TCGA and 
GENIE dataset after stratifying GENIE samples by PCR- and hybridization capture-based approach. The results 
showed inconsistency in mutational profiles with significant differences in the percentage of identified mutations 
and CNAs analyzed by WES, PCR and hybridization capture in ILC and IDC cohorts observed. (Fig. 1(a–c)). 
However, we identified consistency in the mutation frequencies across 40 clinically relevant genes including fre-
quent mutations in PIK3CA, TP53, MAP2K1, NF1 and GATA3 in both of the datasets (Fig. 1(d,e)), which is con-
sistent with previous reports of an association between these gene mutations with breast cancer12. Figure 1(d,e) 
showed the data of all mutations (hotspots and non-hotspots). Hotspot mutations have been annotated with 
COSMIC database and non-hotspots have been annotated with the Oncology Knowledge Base (OncoKB) and 
the Clinical Interpretation of Variants in Cancer (CIViC) databases. We applied the Fisher’s exact test to com-
pare the frequencies for all identified mutations. We observed significant differences between the two datasets in 
some actionable genes such as PIK3CA, ERBB2, TP53, RB1, BRCA2, ESR1, PGR, and ATM, with respect to the 
number of mutations. To further compare the identified somatic mutations from targeted gene panels to WES, we 
first assessed the distribution and prevalence of mutations in ILC and IDC samples. The mutations in each gene 
identified as significant in TCGA dataset were even more prevalent in mutational cluster regions in the GENIE 
dataset in the IDC subtype. The genes that had a higher number of mutations in the GENIE cohort as compared 
to TCGA cohort were BRCA2 (57 versus 12, p-0.035 for missense mutations), NOTCH1 (38 versus 5, p-0.04 for 
missense mutations), and BRCA1 (36 versus 14, p = 0.02 for missense mutations). We also observed 20 mutations 
in the ESR1 gene in the IDC subtype in the GENIE dataset that were not identified in the same tumor subtype 
in TCGA. Among these, the 2 main mutations (D538G and E380Q) confer acquired resistance to aromatase 
inhibitors13. In both cohorts, missense mutations were more prevalent than truncating and inframe mutations 
in both ILC and IDC subtypes (Kruskal-Wallis test, p < 0.0001) (Fig. 1(d,e)). The frequencies, percentages and 
p-values for missense, truncating and inframe mutations in individual genes in ILC and IDC samples are shown 
in Supplementary Tables S1 and S2, respectively.
To measure the prevalence of only hotspot mutations in the TCGA and GENIE datasets, we calculated the 
number of samples in ILC and IDC subtypes that contain =1 and >2 hotspots analyzed by WES and targeted 
sequencing approach (Supplementary Tables S3 and S4, Supplementary Fig. S1). We found the larger number of 
mutational hotspots in GENIE than TCGA which may be related to the deeper coverage of the targeted sequenc-
ing approach. However, we could not find any significant differences for the percentage of individual mutation 
hotspot between two datasets. The TCGA cohort had matched normal controls, however, GENIE samples have no 
matched normal controls. We also searched public databases (COSMIC v8714, hotspots.org15,16 and 3Dhotspots.
org17) as references for evaluating whether the identified mutations through WES and targeted sequencing 
includes any common polymorphisms. We observed that all these hotspots identified in TCGA and GENIE are 
occurring recurrently in COSMIC database and many of those are present in cancer hotspots database, a resource 
for statistically significant mutations in cancer15. We found many novel hotspots in targeted sequencing data that 
have been missed through the WES approach (Supplementary Tables S3 and S4, Supplementary Fig. S1) which 
shows that higher read depth has the potential for higher detection sensitivity of low-level mutations18,19. These 
results demonstrated that target enrichment with higher coverage depths1 ranging from ~200x to 4000x permits 
an in-depth characterization of the genomic landscape to identify rare and low-frequency variants that would 
have been missed by WES.
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TCGA GENIE
ILC (TCGA 
versus 
GENIE) 
p-value
IDC (TCGA 
versus 
GENIE) 
p-value
ILC (TCGA 
versus 
GENIE) 
q-value
IDC (TCGA 
versus 
GENIE) 
q-value
Histological type
ILC 
(n = 127), 
n(%)
IDC 
(n = 490), 
n(%))
ILC 
(n = 248), 
n(%)
IDC 
(n = 1724), 
n(%)
Age
Mean 62.3 57.4 58.9 53 0.66 0.66 0.693 0.693
18–50 29 (22.8%) 163 (33.3%) 63 (25.4%) 734 (42.6%) 0.6141 ****<0.0001 0.6448 0.0001
51–70 60 (47.2%) 242 (49.4%) 142 (57.3%) 859 (49.8%) 0.0798 ****<0.0001 0.1815 0.0001
71–90 38 (29.9%) 85 (17.3%) 41 (16.5%) 129 (7.5%) **0.0033 ****<0.0001 0.009 0.0001
Not Available 
(NA) 0 (0.0%) 0 (0.0%) 2 (0.8%) 2 (0.1%) 0.5509 >0.9999 0.6266 0.4083
Race
White 107 (84.3%) 344 (70.2%) 212 (85.5%) 1320 (76.6%) 0.761 ****<0.0001 0.7397 0.0001
Black 9 (7.1%) 63 (12.9%) 8 (3.2%) 134 (7.8%) 0.1147 ****<0.0001 0.1957 0.0001
Asian 3 (2.4%) 36 (7.3%) 6 (2.4%) 98 (5.7%) >0.9999 ****<0.0001 0.7583 0.0001
Native American 0 (0.0%) 0 (0.0%) 1 (0.4%) 1 (0.1%) >0.9999 >0.9999 0.7583 0.4083
Asian Indian or 
Alaska Native 0 (0.0%) 1 (0.2%) 0 (0.0%) 0 (0.0%) >0.9999 0.2213 0.7583 0.1251
NA 7 (5.5%) 46 (9.4%) 0 (0.0%) 0 (0.0%) ***0.0005 ****<0.0001 0.0023 0.0001
Not Evaluated 1 (0.8%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0.3387 >0.9999 0.4203 0.4083
Other 0 (0.0%) 0 (0.0%) 7 (2.8%) 48 (2.8%) 0.1006 0.3594 0.1957 0.1887
Unknown 0 (0.0%) 0 (0.0%) 14 (5.6%) 123 (7.1%) **0.0033 *0.0496 0.009 0.0304
Ethnicity
Hispanic or Latino 6 (4.7%) 17 (3.5%) 15 (6.0%) 99 (5.7%) 0.8129 ***0.0001 0.7397 0.0001
Not Hispanic or 
Latino 106 (83.5%) 393 (80.2%) 191 (77.0%) 1196 (69.4%) 0.1787 ****<0.0001 0.271 0.0001
NA 14 (11.0%) 80 (16.3%) 0 (0.0%) 0 (0.0%) ****<0.0001 ****<0.0001 0.0007 0.0001
Not Evaluated 1 (0.8%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0.3387 >0.9999 0.4203 0.4083
Unknown 0 (0.0%) 0 (0.0%) 42 (16.9%) 429 (24.9%) ****<0.0001 ****<0.0001 0.0007 0.0001
Tumor grade
T Stage
T1 21 (16.5%) 135 (27.6%) NA NA — — — —
T2 59 (46.5%) 300 (61.2%) NA NA — — — —
T3 46 (36.2%) 30 (6.1%) NA NA — — — —
T4 1 (0.8%) 24 (4.9%) NA NA — — — —
TX 0 (0.0%) 1 (0.2%) NA NA — — — —
N Stage
N0 54 (42.5%) 234 (47.8%) NA NA — — — —
N1 38 (29.9%) 170 (34.7%) NA NA — — — —
N2 13 (10.2%) 53 (10.8%) NA NA — — — —
N3 21 (16.5%) 24 (4.9%) NA NA — — — —
NX 1 (0.8%) 9 (1.8%) NA NA — — — —
M Stage
M0 98 (77.2%) 440 (89.8%) NA NA — — — —
MX 29 (22.8%) 50 (10.2%) NA NA — — — —
Hormone Status
ER status
ER-positive 117 (92.1%) 328 (66.9%) NA NA — — — —
ER-negative 8 (6.3%) 133 (27.1%) NA NA — — — —
Not Evaluated 2 (1.6%) 27 (5.5%) NA NA — — — —
Indeterminate 0 (0.0%) 2 (0.4%) NA NA — — — —
Equivocal 0 (0.0%) 0 (0.0%) NA NA — — — —
PR status
PR-positive 100 (78.7%) 284 (58.0%) NA NA — — — —
PR-negative 24 (18.9%) 176 (35.9%) NA NA — — — —
Not Evaluated 2 (1.6%) 28 (5.7%) NA NA — — — —
Indeterminate 1 (0.8%) 2 (0.4%) NA NA — — — —
Continued
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Comparison of copy number calls in actionable genes in breast cancer tCGA and GeNIe data-
sets. The TCGA Pan-Cancer analysis and other studies have shown that CNAs are one of the hallmarks of 
genomic instability in many cancers and are also the dominant feature in breast cancer20–23. A large-scale genomic 
dataset called the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) has performed 
an integrated analysis by combining gene copy number and expression to identify novel biological subgroups22. 
However, a comprehensive understanding of these alterations as putative predictive biomarkers in clinical prac-
tice should ultimately facilitate the interpretation of patient data for potential targeted therapy. Thus, the accurate 
and unbiased identification of recurring CNAs, which are potentially driver events, by using multiple data sets is 
important to identify the genomic regions of consistent aberration across multiple individuals. We next examined 
to what extent these two platforms were consistent in detecting actionable genomic CNAs at the sample and gene 
level. The Fisher’s exact test was used to evaluate the variability in the frequencies of CNA calls. We observed 
striking differences in the CNA landscape between these two datasets (Fig. 2). The frequencies, percentages and 
p-values for actionable CNAs in ILC and IDC samples are shown in Supplementary Tables S5 and S6, respectively. 
The frequency of copy number gain alterations in FGFR1 across ILC samples was 22-fold higher in the TCGA 
cohort as compared to the GENIE cohort (22% versus 1%, p < 0.0001). RPTOR also harbored frequent copy 
number gain alterations in 15% of TCGA cases compared to GENIE (0%). We also observed higher frequencies 
of patients having hemizygous deletions in the hormone receptors in ILC TCGA data set that were not observed 
in GENIE, including AR (8% versus 0%, p < 0.0001), ESR1 (23% versus 2%, p < 0.0001) and PGR (42% versus 
0%, p < 0.0001) (Fig. 2(a)). The differences in the frequencies of copy number amplifications and deletions within 
actionable genes were also observed in the IDC subtype (Fig. 2(b)). The most frequent actionable alterations in 
the TCGA IDC dataset in comparison to GENIE were amplification in the regions of 15 genes (AKT3, ESR1, 
BARD1, BRCA1, PALB2, CD274, GATA3, NOTCH1, NOTCH4, MET, CDK4, CCND3, CCND2, CCNE1, CDK6, 
p < 0.0001) and deletion in 9 genes (PGR, ATM, BRCA2, BARD1, FGFR1, RB1, BRAF, KRAS, FBXW7, p < 0.05) 
(Fig. 2(b)). These results indicate that SNP array platforms can detect DNA copy number changes to a reasonable 
degree of accuracy. We next applied the two-stage linear step-up procedure of Benjamini, Kreiger, and Yekutieli24 
by setting false-discovery rate (FDR)(Q) to 5% to determine the number of genes with statistically significant 
different proportion of samples with CNAs between the two datasets. Our comparative analysis for ILC revealed 
that 34/40 (85%) genes had significant variance in copy number gain, 3/40 (7%) genes in amplification and 34/40 
(85%) in hemizygous deletion. Likewise, for IDC, we observed differences in 40/40 (100%) genes for gain, 28/40 
(70%) for amplification, 40/40 (100%) genes for hemizygous deletion and 9/40 (22%) genes for homozygous 
deletion. Since chromosomal aberrations are known to be associated with cancer progression25,26, we analyzed 
amplification and deletions separately to assess which fraction of calls would have been missed by SNP-based 
array and targeted sequencing approach. We compared both of the datasets for the identification of significant 
regions of chromosomal amplification and deletions using GISTIC algorithm on the segmented data. The most 
significant regions (q < 0.25) of copy number amplification in actionable genes were found in GENIE dataset as 
compared to TCGA dataset in ILC (Fig. 3(a–c)) and IDC cohorts (Fig. 4(a–c)). For deletions, we found common 
and distinct regions that were deleted in breast cancer-associated genes in both datasets in the ILC (Fig. 3(d–f)) 
and IDC cohorts (Fig. 4(d–f)). The results of this analysis showed that several potentially important copy number 
amplifications were capable of being better detected by hybridization capture than SNP-based arrays.
Comparison of the number of mutational hotspots and copy number calls in actionable genes 
in NSCLC and colorectal cancer TCGA and GENIE datasets. We further evaluated whether these 
differences in CNAs were specific for breast cancer or due to tissue preservation methods or platform-specific 
artifacts. To address this question, we compared the TCGA WES and SNP array data generated from fresh fro-
zen tissues in colorectal27 and non-small cell lung cancer (NSCLC)28 with the corresponding cancer type in the 
GENIE targeted panel data obtained from FFPE tissues. We found that there was inconsistency in the frequency 
distribution of CNAs in both of the data sets for those actionable genes from our list which are considered prom-
ising druggable targets for NSCLC, and colorectal cancer, such as KRAS, BRAF, EGFR, ATM, and PIK3CA. In 
NSCLC alone, we observed higher frequencies of CNAs in many actionable genes in TCGA than in GENIE, such 
as FGFR1 (9% versus 2%, p < 0.0001) and PIK3CA (18% versus 1%, p < 0.0001) for amplification and CDKN2A 
(13% versus 0%, p < 0.0001), CDKN2B (20% versus 4%, p < 0.0001) for deletions (Fig. 5(a)). In colorectal cancer, 
TCGA GENIE
ILC (TCGA 
versus 
GENIE) 
p-value
IDC (TCGA 
versus 
GENIE) 
p-value
ILC (TCGA 
versus 
GENIE) 
q-value
IDC (TCGA 
versus 
GENIE) 
q-value
Equivocal 0 (0.0%) 0 (0.0%) NA NA — — — —
HER2 status
HER2-positive 9 (7.1%) 82 (16.7%) NA NA — — — —
HER2-negative 71 (55.9%) 243 (49.6%) NA NA — — — —
Not Evaluated 22 (17.9%) 71 (14.5%) NA NA — — — —
Indeterminate 1 (0.8%) 5 (1.0%) NA NA — — — —
Equivocal 24 (18.9%) 83 (16.9%) NA NA — — — —
NA 0 (0.0%) 6 (1.2%) NA NA — — — —
Table 1. Clinicopathological features of the TCGA and GENIE cohorts. *Significant p-value.
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Figure 1. Overview of the genomic alterations in breast cancer patients in the TCGA and GENIE cohort (a) Bar 
graph maps depicting the percentage of cases with mutations obtained from WES (TCGA dataset) versus targeted 
gene panel (combined data of PCR and hybridization capture, GENIE dataset) approach in 40 actionable genes in 
ILC and IDC subtypes. (b) Bar graph maps depicting the percentage of cases having mutational hotspots obtained 
from WES (TCGA dataset) versus PCR and hybridization capture (GENIE dataset) in ILC and IDC subtypes (c) 
Bar graph maps depicting the percentage of cases with CNAs obtained from the SNP-based array (TCGA dataset) 
versus targeted gene panel (hybridization capture, GENIE dataset) approach in 40 actionable genes in ILC and IDC 
tumors. (d) Percentage of mutations in 40 actionable genes in TCGA and GENIE ILC patient samples analyzed 
by WES versus PCR and hybridization capture technique. PIK3CA dominated the mutational landscape in both 
data sets and missense mutations (i.e. nontruncating) were more prevalent than truncating and inframe mutations. 
The inset shows the variation in the percentages of missense, truncating and inframe mutations in the TCGA 
and GENIE cohort in ILC subtype. (e) Percentage of mutations in 40 actionable genes in TCGA and GENIE IDC 
patients. TP53 was the most commonly mutated gene in TCGA and GENIE IDC patients. The inset shows the 
variation in the percentages of missense, truncating and inframe mutations in the TCGA and GENIE cohort in 
IDC tumors. In both cohorts, missense mutations were more prevalent than truncating and inframe mutations in 
both ILC and IDC tumors (Kruskal-Wallis test, ****p < 0.0001).
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the genes that were significantly enriched for copy number gain in TCGA versus GENIE were BRCA2 (60% 
versus 23%, p < 0.0001), BRAF (48% versus 11%, p < 0.0001) and KRAS (22% versus 3%, p < 0.0001) (Fig. 5(b)).
In NSCLC and CRC, we observed no significant differences between the proportion of mutations in action-
able genes identified through WES and targeted sequencing approach. However, the total number of mutations 
(including missense, truncating and inframe) in the TP53 gene was greater in GENIE than in TCGA (1709 versus 
791, p < 0.0001). Larger number of hotspots and non-hotspots were also detected in GENIE in the NSCLC dataset 
for genes such as EGFR (738 versus 122, p < 0.0001), NF1 (211 versus 131, p < 0.0001) and PIK3CA (237 versus 
94, p-0.038) in comparison to TCGA. Likewise, TP53 was highly enriched for mutations in the GENIE colorectal 
cancer data as compared to TCGA data (1629 versus 122, p-0.0064). We also observed higher number of muta-
tional hotspots in 3 actionable genes in KRAS (1164 versus 219, p < 0.0001, q-0.0005), EGFR (814 versus 103, 
p < 0.0001, q-0.0005) and TP53 (1195 versus 499, p < 0.0001, q-0.0005) in GENIE than in TCGA in NSCLC cases.
Discussion
This study represents an integrated comparison of whole exome, SNP-based array and targeted gene panel 
sequencing in terms of their ability to detect mutations and CNAs in potentially clinical actionable genes from 
two-large breast cancer cohort studies. We observed that targeted sequencing is more effective in detecting CNAs 
than SNP-based array. Although targeted capture sequencing focused on hotspot regions and provided increased 
quality and reliability at a greater depth in comparison to whole genome sequencing (WGS)29,30, it identified only 
smaller insertions and deletions while ignoring large duplications and deletions31. RNA sequencing data was not 
available from the GENIE dataset and thus it was difficult to determine whether the identified mutational hot-
spots and gene dosage are related to gene expression. The differences are attributable to the methodology used in 
both datasets and due to the limited capture design in targeted gene panel and an unequal distribution of targeted 
sites across the genome that would result in a large number of false positive and false negative calls. These results 
may be used as a better benchmark for future studies aimed at the identification of actionable alterations from the 
comparison of large-scale genomic data sets.
We observed that the percent of tumors with CNAs was quite small in GENIE as compared to TCGA, making 
it difficult to determine the precise spectrum of actionable alterations. The low frequencies in CNAs in these FFPE 
samples may also be explained due to low input of DNA and degraded DNA that makes the detection procedure 
complicated for the identification of the regions of deletion. Schweiger et al.32 have shown that higher sequenc-
ing coverage is required for CNA analysis. Although GENIE has also used higher sequencing coverage to detect 
CNAs, however, there are low frequencies in CNAs in breast cancer, NSCLC and CRC FFPE samples in compar-
ison to TCGA fresh-frozen tissues. Studies have also shown that copy number analysis between the fresh-frozen 
and FFPE samples varied to a certain degree suggesting that discrepancy in the CNAs frequencies can be due to 
tissue-preservation methods33,34. Another important factor affecting CNA detection is the amount of input DNA 
that is more than ten-fold higher for the array-based method than sequencing. Thus, the choice of assay and tissue 
preservation method is important for accurately detecting mutations and CNAs to guide treatment decisions. 
The MSK-IMPACT tumor profiling assay may distinguish mismatch repair deficiency (MMR-D) and proficient 
(MMR-P) tumors on the basis of mutational burden in colorectal cancer35. The implementation of the results 
from these platforms in a clinical diagnostic environment requires immunohistochemistry (IHC) validation per 
multiple guidelines36–38. Due to the large variation in detecting genomic alterations between different platforms, 
many studies have suggested that using multiple computational methods for the identification of genomic alter-
ations reduces the chances of false positive results39,40. Recently, Shi et al.41 identifies that 69% of the mutations 
from tumor-only WES pipeline were false-positive and even for matched-normal DNA only 36–78% were found 
consistently in replicate pairs. Since the TCGA cohort is having with or without matched normal controls and 
GENIE samples have no matched normal controls suggests that caution should be exercised when interpreting 
these genomic alterations. Torga and colleagues reported very low congruence in tumor-specific genetic altera-
tions for patient-paired samples between the PlasmaSELECT and Guardant360 tests that could lead to different 
treatment decisions42. These results showed that genetic sequencing assays are not always concordant even when 
the exact same samples are processed, likely due to inherent differences in assay platforms.
From a clinical point of view, our results are of high importance in terms of assessing CNAs from SNP-based 
array in clinical laboratories, with a particular focus on amplifications in CNAs that would have been missed by 
this approach. The differences in the CNAs frequency across different platforms would also affect the ability to 
identify the subtype-specific patterns of alterations (for example, TERT amplification in lung cancer squamous 
cell carcinoma43) and the driver genes that have been mutated by genomic duplication and deletion. Our results 
highlight some of the issues associated with technical inconsistencies in using molecular profiling for clinical 
decision-making. NGS technologies continue to evolve with improvements in accuracy along with the rapid 
production of huge datasets and new methods for identification of recurrent CNAs in multiple samples. However, 
it is difficult to assess the relative strengths and limitations of different sequencing methods because of the lack 
of studies that comprehensively compare these technologies. Despite this, variations in the interpretation of copy 
number changes between the sequencing platforms may become a problem not only for researchers who need 
to select the method for a dataset of interest, but also a big challenge for clinicians: which platform (array versus 
NGS) might best detect the underlying genetic driver of the disease in patients? These differences pose a seri-
ous challenge when trying to apply these technologies in clinical trials due to the confounding results, which 
may further impact on treatment decisions for cancer patients. Although both the TCGA and GENIE genomic 
datasets have CLIA/CAP certifications, validation steps are needed for both the wet and dry bench workflow of 
NGS-based assays independently by the clinical laboratory before implementation. Furthermore, the platform 
selection should be based on cross-validating these technologies with more reliable methods such as fluorescence 
in situ hybridization (FISH) and real-time PCR. There is also a need for more specific guidelines to interpret the 
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clinical significance of actionable CNAs detected by array and NGS technologies for improved “genomic-based” 
therapeutic approaches for cancer patients.
Figure 2. Differential pattern of CNAs in actionable genes in the TCGA and GENIE cohort across ILC and 
IDC subtypes (a) Bars depict the proportion of tumors with CNAs in potentially actionable genes altered in ILC 
samples. The percentage of tumors with hemizygous deletion (grey), homozygous deletion (yellow), low-level 
gain (blue) and high-level amplification (red) are shown. (b) Bars depict the proportion of tumors with CNAs in 
potentially actionable genes altered in IDC samples. The percentage of tumors with hemizygous deletion (grey), 
homozygous deletion (yellow), low-level gain (blue) and high-level amplification (red) are shown.
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Figure 3. Significant CNAs in ILC cohort in the TCGA and GENIE datasets. (a) GISTIC analysis of significant 
amplifications (red) determined by segmentation analysis from SNP-based array in TCGA ILC cohort. The 
statistical significance of the aberrations is displayed as FDR (q-values) and scores for each alteration are given 
at x-axis. The cut-off for significant threshold is 0.25 (green line). The y-axis indicates the chromosome positions 
and dotted lines indicate the centromeres. (b) GISTIC analysis of significant amplifications (red) determined by 
segmentation analysis from hybridization capture technique in GENIE ILC cohort. (c) The heat map represents 
significant amplified regions in ILC patients in the TCGA and GENIE datasets. The genes from our potential 
actionable gene list are given in parentheses. (d) GISTIC analysis of significant deletions (blue) determined by 
segmentation analysis from SNP-based array in TCGA ILC cohort. (e) GISTIC analysis of significant deletions 
(blue) determined by segmentation analysis from hybridization capture technique in GENIE ILC cohort. (f) 
The heat map represents significant deleted regions in ILC patients in the TCGA and GENIE datasets. The genes 
from our potential actionable gene list are given in parentheses.
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Figure 4. Significant CNAs in IDC cohort in the TCGA and GENIE datasets. (a) GISTIC analysis of significant 
amplifications (red) determined by segmentation analysis from SNP-based array in TCGA IDC cohort. The 
statistical significance of the aberrations is displayed as false-discovery rate (q-values) and scores for each 
alteration are given at x-axis. The cut-off for significant threshold is 0.25 (green line). The y-axis indicates 
the chromosome positions and dotted lines indicate the centromeres. (b) GISTIC analysis of significant 
amplifications (red) determined by segmentation analysis from hybridization capture technique in GENIE IDC 
cohort. (c) The heat map represents significant amplified regions in IDC patients in the TCGA and GENIE 
datasets. The genes from our potential actionable gene list are given in parentheses. (d) GISTIC analysis of 
significant deletions (blue) determined by segmentation analysis from SNP-based array in TCGA IDC cohort. 
(e) GISTIC analysis of significant deletions (blue) determined by segmentation analysis from hybridization 
capture technique in GENIE IDC cohort. (f) The heat map represents significant deleted regions in IDC patients 
in the TCGA and GENIE datasets. The genes from our potential actionable gene list are given in parentheses.
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The major limitation of this study is that raw files are not available for the GENIE dataset. In addition, there 
was much variation in the underlying research strategy of these two datasets such as coverage of the sequenc-
ing platforms, different variant calling pipelines and different assays. Differences in the tools/algorithm used in 
Figure 5. Differential pattern of CNAs in actionable genes in the TCGA and GENIE cohort across NSCLC and 
colorectal cancer. (a) Bars depict the proportion of tumors with CNAs in potentially actionable genes altered 
in NSCLC samples. (b) Bars depict the proportion of tumors with CNAs in potentially actionable genes altered 
in colorectal cancer samples. The percentage of tumors with hemizygous deletion (grey), homozygous deletion 
(yellow), low-level gain (blue) and high-level amplification (red) are shown. The Fisher’s exact test was used to 
determine whether the frequencies of CNAs are different in potentially actionable genes between TCGA and 
GENIE datasets analyzed by the array and NGS-based technologies.
www.nature.com/scientificreports/
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the different steps along with the variant-calling pipelines may also impact the frequency of variants identified. 
Considering these constraints, we set out to make a comparison demonstrating the frequency of variants using 
only the processed data as that was available for both datasets through cBioportal.
In conclusion, our study provides an integrated comparison of array and NGS technologies in identifying 
clinically relevant genomic alterations in potentially actionable genes. We compared the DNA sequencing data 
between the TCGA and GENIE project to evaluate the concordance in the frequencies of mutations and signif-
icant patterns of CNAs in clinically relevant genes in two breast cancer subtypes. Our results showed that SNP 
array platform identified many candidate regions of CNAs in actionable genes. We found that targeted gene panel 
sequencing was more effective in detecting a larger number of mutational hotspots and clinically significant 
duplications and deletions that were missed by WES and SNP-based array. The results of our study may be used 
as a better benchmark for future studies aimed at the identification of actionable alterations from the comparison 
of large-scale genomic data sets.
Methods
Analysis of potentially breast cancer related genes. For both large-scale genomic datasets, we 
identified a panel of 49 potentially actionable targets in which biomarkers were linked with FDA-approved or 
investigational therapeutics in breast cancer studies listed on www.clinicaltrials.gov (Table 2). We analyzed the 
TCGA44 and GENIE1 datasets from primary invasive lobular carcinomas (ILC) and invasive ductal carcinomas 
(IDC) patients for 40 genes from our curated list as 9 genes were not available on the targeted gene panel. Genes 
were defined as clinically relevant or actionable based on therapeutic and/or diagnostic implications in cancer 
patients45. Our gene panel is not Clinical Laboratory Improvement Amendments (CLIA)/College of American 
Pathologists (CAP) certified, but the majority of these 49 actionable targets are found in CLIA certified gene 
panels such as the Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-
IMPACT) (410 genes), OncoKB database46 (476 cancer-associated genes targeted by FDA-approved drugs or 
standard therapeutic agents) and Foundation Medicine (315 clinically relevant genes). The intent of our gene 
panel was to focus on potentially actionable genes with relevance to breast cancer and to maintain a sufficiently 
focused list in order to permit a detailed comparison of the TCGA and GENIE results as they pertain to clinically 
relevant gene targets.
TCGA and GENIE data. We assessed the whole-exome DNA sequencing and Affymetrix SNP 6.0 array 
data for 127 ILC and 490 IDC from TCGA cohort and compared these with the third data release for GENIE 
targeted sequencing data for 248 ILC and 1724 IDC cases. The mutations and CNAs generated from Affymetrix 
array and NGS technologies were retrieved from cBioportal47,48. Only GENIE samples that were screened using 
hybridization-based capture approach, as opposed to PCR-based approach, were analyzed for CNAs. The sample 
size of this subset of GENIE samples analyzed for CNAs is given in Supplementary Table S7. All patient samples 
were de-identified and encoded with TCGA and GENIE sample codes. We compared the array and NGS results 
from TCGA fresh frozen tissues and GENIE FFPE tissues to determine concordance between each platform. 
For the validation of both datasets, we also compared the TCGA WES and SNP array data generated from fresh 
frozen tissues in colorectal27 and non-small cell lung cancer (NSCLC)28 with the corresponding cancer type in 
the GENIE targeted panel data1 obtained from FFPE tissues. We obtained the mutational and CNA events using 
cBioPortal for array data from TCGA NSCLC (n = 1144) and targeted gene panel sequencing data from GENIE 
(n = 3694). The mutational and CNA events for colorectal cancer were also obtained from cBioPortal for array 
data from TCGA colorectal (n = 226) and targeted gene panel sequencing data from GENIE (n = 2574).
Comparison of DNA mutations from WES and targeted gene panel sequencing data. For the 
identification of putative hotspots in clinically actionable genes, we downloaded the mutational hotspot data for 
TCGA and GENIE cohorts using cBioportal from the sequenced exomes of breast cancer patients (based on pre-
specified classifications or groups). The Fisher’s exact test was used to evaluate the variability in the frequencies of 
mutations for 40 actionable genes between both data sets for ILC and IDC subtypes. The Kruskal-Wallis test was 
applied to assess which mutation types are more prevalent in both breast cancer subtypes.
Comparison of CNAs from SNP-based array and targeted gene panel sequencing data. To 
determine the copy number status of an individual gene in any given patient, we used copy number datasets 
within the cBioportal generated by Genomic Identification of Significant Targets in Cancer (GISTIC) algo-
rithms26. CNA was characterized by measured copy number (expressed as a log2 ratio), and by the extent of 
change in the genome. The CNA thresholds were determined according to the set of discrete copy number calls 
provided by GISTIC: deep loss/homozygous deletion (−2), shallow loss/hemizygous deletion (−1), low-level gain 
(1), and high-level amplification (2). The copy number data was not available from the patients analyzed by PCR 
method in GENIE data set. The Fisher’s exact test was used to determine whether the frequencies of CNAs are 
different in actionable genes between TCGA and GENIE datasets analyzed by the array and NGS-based technolo-
gies. The identification of significantly amplified and deleted regions among potentially actionable genes was done 
using the GISTIC algorithm. The data was aligned to genome build hg19. The algorithm was executed within the 
Broad Firehose infrastructure. The GISTIC analysis was conducted separately on the ILC and IDC subtypes in 
TCGA and GENIE breast cancer study.
Statistical Analysis. Statistical analysis for comparing the mutations and CNAs was performed using 
GraphPad Prism version 7. The most prevalent mutations among missense, truncating and inframe mutations 
were calculated using the Kruskal-Wallis test. The Fisher’s exact test was used to calculate the variability for the 
frequencies of hotspots and CNAs. The two-stage linear step-up procedure of Benjamini, Kreiger and Yekutieli by 
setting FDR(Q) to 5% was used to correct p-values for multiple testing.
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IMPACT OncoKB Clinical Trials Candidate Drugs
PIK3CA P P P NCT02465060, NCT03337724, NCT01513356, NCT01337765, NCT01928459, NCT03243331
Buparlisib, Alpelisib + Fulvestrant, Serabelisib, 
Copanlisib, GDC-0077, Alpelisib
AKT3 P P —
NCT01964924, NCT02162719, NCT01226316, 
NCT02077569, NCT01277757, NCT02423603, 
NCT01980277, NCT01964924, NCT01992952
Taselisib + Fulvestrant, Buparlisib + Fulvestrant, 
Taselisib, GDC-0941
NF1 P P P NCT02465060 Ipatasertib, BKM120, BEZ235, BGJ398 with BYL719, Gedatolisib
PIK3CB P P — NCT02465060, NCT03337724, NCT01513356, NCT01337765, NCT01928459, NCT03243331 —
RPTOR — — —
NCT02456857, NCT01674140, NCT00107016, 
NCT02465060, NCT02583542, NCT01390818, 
NCT01337765
Ipatasertib, AZD5363, PF-04691502, Triciribine, 
CCT128930
AKT1 P P P
NCT01964924, NCT02162719, NCT01226316, 
NCT02077569, NCT01277757, NCT02423603, 
NCT01980277, NCT01964924, NCT01992952
Honokiol, AT13148, TIC10 (ONC201), MK2206
FBXW7 P P — — LY2780301, GSK2141795
IGF1 P P —
NCT00984490, NCT02278965, NCT01479179, 
NCT00984490, NCT00759785, NCT01372618, 
NCT00897884
—
GRB7 — — — NCT00513292, NCT00004067 LTT462, Binimetinib, BVD523, Trametinib,
KRAS P P P NCT00894504, NCT02259114, NCT01520389, NCT01337765
MAPK/PI3K/mTOR inhibitors, e.g., 
MSC1936369B
BRAF — P P NCT02401347, NCT03065387, NCT01363232, NCT01337765 Everolimus, Temsirolimus
EGFR P P P
NCT02465060, NCT01582191, NCT01934335, 
NCT01732276, NCT00739063, NCT02720185, 
NCT00820924, NCT00894504
—
MAP2K1 P P P NCT02322814, NCT01160718, NCT02685657, NCT00147550, NCT01467310, NCT01337765
Buparlisib, Alpelisib + Fulvestrant, Serabelisib, 
Copanlisib, GDC-0077
JAK2 P P P NCT02041429, NCT02637375, NCT01929941 Alpelisib, Taselisib + Fulvestrant, Buparlisib + Fulvestrant, Taselisib
ERBB2 P P P NCT02465060, NCT03065387, NCT00878709, NCT01953926, NCT00875979
GDC-0941, Ipatasertib, BKM120, BEZ235, 
BGJ398 with BYL719, Gedatolisib
ERBB3 — P —
NCT03065387, NCT00073528, NCT02980341, 
NCT02297698, NCT01918254, NCT03321981, 
NCT00073528
—
CCND1 P P — NCT02936206, NCT03304080, NCT01740427, NCT02187783, NCT01037790
Everolimus, AZD8055, Becacizumab, Voxtalisib, 
PP242
CDKN2A P P P NCT01740427 OSI-027, Apitolisib, Gedatolisib (PKI-587), Sapanisertib
CDKN2B P P — NCT01740427 AZD6244, SAR245409, BEZ235
CCND3 P P — NCT02187783 —
CCND2 P P — NCT01037790, NCT00334542, NCT02187783 Ipatasertib, AZD5363, PF-04691502, Triciribine, CCT128930
CCNE1 P P — NCT03184090 Honokiol, AT13148, TIC10 (ONC201), MK2206, LY2780301
CDK6 P P — NCT03184090 GSK2141795
CDK4 P P P NCT03184090 —
TP53 P P — NCT00044993, NCT00004038, NCT01386502, NCT00496860 —
RB1 P P — NCT02599363, NCT03130439, NCT03007979 Tivozanib, AMG 479, Metformin, MK-0646, Pasireotide, Ganitumab
NOTCH4 — — — NCT00645333, NCT01372579 G7–18NATE, NVP-AEW541, BMS-536924, BMS-536924, Dovitinib
NOTCH1 P P —
NCT02299635, NCT01208441, NCT00645333, 
NCT01372579, NCT00106145, NCT01151449, 
NCT01071564
Cobimetinib, Trametinib, AZD6244, 
MSC1936369B
ALDH1A1 — — — NCT01190345, NCT01424865, NCT00949013, NCT01688609, NCT02001974, NCT01372579 Selumetinib, PD-325901, GSK1120212, MEK162
MET P P P NCT02465060, NCT03316586, NCT01837602, NCT01575522, NCT01138384 —
FGFR1 P P — NCT01283945 Cobimetinib, Vemurafenib, Dabrafenib,Trametinib
FGFR2 P P — NCT01283945 BKM120 Plus MEK162, BEZ235 Plus MEK162
WNT1 — — — NCT03243331, NCT01351103 ″
ATM P P P NCT02401347, NCT03344965 Afatinib, Erlotinib, Gefitinib, Osimertinib, Vandetanib, Dasatinib, Lapatinib, Panitumumab
Continued
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Ethics approval and consent to participate. This study was performed in strict accordance with the 
recommendations of data access guidelines of TCGA and AACR project GENIE datasets. We received admin-
istrative permission for downloading the restricted-access data for breast cancer patients from the TCGA Data 
Access Committee (Project # 10345).
Data Availability
The datasets analyzed in the current study are publicly available in cBioportal and sage synapse platform.
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